A new drug for advanced lung cancer that hasn't been treated yet
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug called SSGJ-707 for people with advanced non-small cell lung cancer who have not had prior treatment. It aims to see if the drug can help shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have stage IIIB, IIIC, or IV non-small cell lung cancer that has not been treated with systemic therapy.
- You must be able to care for yourself (ECOG score 0 or 1).
- You cannot have certain genetic mutations like EGFR, ALK, BRAF, MET, NTRK, RET, or ROS1.
- You cannot have cancer spread to the brain stem, spinal cord, or lining of the brain.
- You cannot have active tuberculosis, HIV, or a history of severe allergies to antibody drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This trial tests a new drug combination for people with advanced non-small cell lung cancer (NSCLC) that cannot be removed with surgery or cured with radiation. It aims to see if the combination is safe and effective.
This trial tests a new drug called JSKN016 for people with advanced non-small cell lung cancer (NSCLC) that has not responded to standard treatments. It may help those with certain gene changes or after prior therapy has failed.
This trial tests a new drug called SSGJ-706, either alone or with other treatments, for people with advanced non-small cell lung cancer (NSCLC) that has spread or cannot be surgically removed. The goal is to see if it helps shrink or control the cancer.
This trial tests a new drug called SSGJ-705, given alone or with other treatments, for advanced cancers that have a specific protein (HER2) on their surface. It is for people with lung, breast, or stomach cancer that has spread and hasn't gotten better with other treatments.
This trial tests a new drug (JS207) that targets both PD-1 and VEGF pathways, given alone or with other treatments, for people with advanced non-small cell lung cancer that has a specific gene change and has stopped responding to targeted therapy (TKI). The goal is to see if this combination can help shrink tumors or slow cancer growth.
Hear when a new Advanced Non-Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.